11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI) (Q24194742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

meta-analysis

0 references

title

(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

0 references

mild cognitive impairment

1 reference

inferred from title

cognitive dysfunction

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Shuo Zhang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

Chris Hyde

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

Anna H Noel-Storr

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

Rupert McShane

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

Juan Feng

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

Nadja Smailagic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

publication date

23 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

CD010386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Cognitive decline and amyloid accumulation in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Impact of molecular imaging on the diagnostic process in a memory clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid imaging in mild cognitive impairment subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Longitudinal Patterns of β-Amyloid Deposition in Nondemented Older Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid imaging with (11)C-PIB PET/CT and glucose metabolism with (18)F-FDG PET/CT in a study on cognitive impairment in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Clinical features of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Identification of normal and pathological aging in prospectively studied nondemented elderly humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Does a positive Pittsburgh Compound B scan in a patient with dementia equal Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

In vivo amyloid imaging with PET in frontotemporal dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Frontotemporal dementia: clinicopathological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid imaging of Lewy body-associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Researchers test strategies to prevent Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Brain amyloid and cognition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Enrichment and stratification for predementia Alzheimer disease clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Evaluation of diagnostic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

The Clinical Dementia Rating (CDR): current version and scoring rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mild cognitive impairment: ten years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Age, neuropathology, and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mixed brain pathologies account for most dementia cases in community-dwelling older persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

The neuropathology of probable Alzheimer disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations

21 January 2018

1 reference

12 December 2020

Is MCI really just early dementia? A systematic review of conversion studies.

1 reference

12 December 2020

Ten-year risk of dementia in subjects with mild cognitive impairment

1 reference

12 December 2020

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

1 reference

12 December 2020

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment

1 reference

12 December 2020

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects

1 reference

12 December 2020

Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease

1 reference

12 December 2020

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

12 December 2020

Multimodal Imaging of Alzheimer Pathophysiology in the Brain′s Default Mode Network

1 reference

12 December 2020

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study

1 reference

12 December 2020

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot

1 reference

12 December 2020

The usefulness of amyloid imaging in predicting the clinical outcome after two years in subjects with mild cognitive impairment.

1 reference

12 December 2020

A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved

1 reference

12 December 2020

The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia staging

1 reference

12 December 2020

Pittsburgh compound B retention and progression of cognitive status--a meta-analysis

1 reference

12 December 2020

Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations

1 reference

12 December 2020

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

1 reference

https://api.crossref.org/works/10.1002/14651858.CD010386.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD010386.PUB2

2 references

Consolidated OpenCitations Corpus – April 2017

3498611

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

3498611

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25052054 AND SRC:MED&resulttype=core&format=json

10 March 2020

PubMed publication ID

25052054

2 references

Consolidated OpenCitations Corpus – April 2017

3498611